Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00648947 · ClinicalTrials.gov registry record · Phase 1

Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

A Phase 1 study of Healthy, sponsored by Mylan Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
46
Enrollment target
1
Study location

NCT00648947: Completed Phase 1 study of Healthy, sponsored by Mylan Pharmaceuticals.

NCT00648947 is a Phase 1 study of Healthy that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 46 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00648947, a Phase 1 study of Healthy, has completed, sponsored by Mylan Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
46 participants
Enrollment target
1
Study location

Study Summary

The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single, oral 75 mg (1 x 75 mg) dose administered under fasting conditions.

Conditions Studied

Interventions

  • DRUG Clopidogrel Bisulfate Tablets 75 mg
  • DRUG Plavix® Tablets 75 mg

Study Locations (1)

West Virginia

  • Kendle International Inc. - Morgantown

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2004-12
Est. Completion 2004-12
Phase Phase 1
Mylan Pharmaceuticals

146 total trials

What the finished NCT00648947 record still lists

NCT00648947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Clopidogrel Bisulfate Tablets 75 mg is the first listed.

NCT00648947 reports a single indexed study location in West Virginia.

Frequently Asked Questions

What is clinical trial NCT00648947 about?

NCT00648947 is a clinical study titled "Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg". The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single, oral 75 mg (1 x 75 mg) dose administered under fasting conditions.

What is the current status of trial NCT00648947?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2004-12. Estimated completion is 2004-12.

What conditions does trial NCT00648947 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00648947?

The interventions under investigation include: Clopidogrel Bisulfate Tablets 75 mg (DRUG), Plavix® Tablets 75 mg (DRUG).

Who is sponsoring clinical trial NCT00648947?

This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00648947 being conducted?

This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00648947's enrollment target sits among peer trials

46 494th of 1090 higher than 592 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01890590 · 46 participants · NA

    A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • NCT03191149 · 46 participants · Phase 2

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • NCT03510208 · 46 participants · Phase 1

    Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

  • NCT04048278 · 46 participants · Early Phase 1

    Lidocaine Infusion in Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00648947, the US trial registry maintained by the National Library of Medicine. NCT00648947 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.